30.06

0.17% 0.05

After Hours: 30.06

Tectonic Therapeutic Inc (TECX)

Overview News Price History Discussions Forecast

Tectonic Therapeutic Inc stock is traded at $30.06, with a volume of 190.39K. It is up +0.17% in the last 24 hours and up +7.78% over the past month. Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Previous Close:

$30.01

Open:

$30.06

24h Volume:

190.39K

Relative Volume:

0.94

Market Cap:

$567.21M

Revenue:

Net Income/Loss:

$-83.49M

P/E Ratio:

-6.7444

EPS:

-4.457

Net Cash Flow:

$-60.29M

1W Performance:

+7.17%

1M Performance:

+7.78%

6M Performance:

+67.65%

1Y Performance:

+46.56%

1-Day Range:

$29.14

$31.20

1-Week Range:

$27.30

$31.20

52-Week Range:

$14.38

$36.03

Tectonic Therapeutic Inc Stock (TECX) Company Profile

Name

Tectonic Therapeutic Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(339) 666-3320

Address

490 ARSENAL WAY, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

TECX's Discussions on Twitter

Compare TECX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TECX Tectonic Therapeutic Inc	30.06	554.57M	0	-83.49M	-60.29M	-4.457
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Tectonic Therapeutic Inc Stock (TECX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Initiated	Stifel	Buy
Oct-20-25	Initiated	Wells Fargo	Overweight
Sep-03-25	Initiated	Oppenheimer	Outperform
Jul-21-25	Initiated	Truist	Buy
Jun-11-25	Resumed	Raymond James	Outperform
Apr-21-25	Initiated	Mizuho	Outperform
Nov-20-24	Initiated	Raymond James	Outperform
Aug-22-24	Initiated	Wells Fargo	Overweight
Jun-26-24	Initiated	Piper Sandler	Overweight
Jun-24-24	Initiated	TD Cowen	Buy
Dec-18-23	Downgrade	Mizuho	Buy → Neutral
Jan-05-22	Downgrade	BTIG Research	Buy → Neutral
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-15-21	Initiated	BTIG Research	Buy
May-27-21	Initiated	Needham	Buy
Mar-09-21	Initiated	Barclays	Overweight
Mar-02-21	Initiated	Stifel	Hold
Nov-11-20	Initiated	Berenberg	Buy
Mar-31-20	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-27-19	Initiated	Mizuho	Buy
Apr-05-19	Initiated	Janney	Buy
Oct-10-18	Initiated	Guggenheim	Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy
Sep-17-18	Initiated	H.C. Wainwright	Buy
Jul-16-18	Initiated	Wedbush	Outperform
Jul-16-18	Initiated	Wells Fargo	Outperform

View All

Tectonic Therapeutic Inc Stock (TECX) Latest News

Jun 12, 2026

Tectonic Therapeutic (TECX) CFO receives 7,500 performance stock options at $16.80 - Stock Titan

Jun 12, 2026

Jun 11, 2026

Analysts Are Bullish on Top Healthcare Stocks: Humacyte (HUMA), Tectonic Therapeutic (TECX) - The Globe and Mail

Jun 11, 2026

Jun 10, 2026

Tectonic completes enrollment in TX45 pulmonary hypertension trial - Investing.com UK

Jun 10, 2026

Tectonic completes enrollment in TX45 pulmonary hypertension trial By Investing.com - Investing.com Australia

Jun 10, 2026

Tectonic Therapeutic Completes Enrollment in Key TX45 Trial - TipRanks

Jun 10, 2026

Tectonic Therapeutic (TECX) finishes TX45 Phase 2 APEX enrollment, sets early Q1 2027 data - Stock Titan

Jun 10, 2026

Director at Tectonic Therapeutic (TECX) awarded 10,200 options - Stock Titan

Jun 10, 2026

Director at Tectonic Therapeutic (TECX) granted 10,200 stock options - Stock Titan

Jun 10, 2026

Tectonic Therapeutic (TECX) director receives 10,200 stock options at $28.56 - Stock Titan

Jun 10, 2026

Director at Tectonic Therapeutic (TECX) receives 10,200 stock options expiring 2036 - Stock Titan

Jun 10, 2026

Tectonic Therapeutic (TECX) awards 20,400 stock options to director - Stock Titan

Jun 10, 2026

New Tectonic Therapeutic (TECX) director Jessica Chutter files initial Form 3 - Stock Titan

Jun 10, 2026

Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients - GlobeNewswire

Jun 10, 2026

Jun 09, 2026

Tectonic Therapeutic (TECX) Slides 2.61% as Biotech Sector Faces PressureEquity Put Call - newsline.com

Jun 09, 2026

Jun 08, 2026

TECX: All proposals passed, with directors reelected and auditor ratified; no shareholder questions - TradingView

Jun 08, 2026

Jun 04, 2026